Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion.

To retrospectively evaluate the re-injection interval, efficacy and safety of dexamethasone (DEX) intravitreal implant 0.7 mg in the treatment of macular oedema (ME) due to retinal vein occlusion (RVO) in Germany in 2009-2012.
Retrospective, multicentre, anonymised observational study of data collected from the first DEX implant 0.7 mg injection through 3-6 months following the last injection. Data were included if the patient was >18 years old, had a diagnosis of ME secondary to branch or central RVO, and received at least 2 DEX implant 0.7 mg injections during routine practice.
Data from 87 patients were analysed. Mean time to re-injection between first and second treatments was 5.03 months in the total RVO population, and 5.46 and 4.52 months for the branch and central RVO subpopulations, respectively. An intraocular pressure increase of >25 mm Hg was recorded in 20% of patients, and 34% of patients began treatment with anti-glaucoma medication, but surgery was not needed for this condition.
DEX implant 0.7 mg was found to be well tolerated and effective with repeat treatments in clinical practice.
AuthorsAlbert J Augustin, Frank G Holz, Christos Haritoglou, Wolfgang J Mayer, Silvia Bopp, Alexander F Scheuerle, Matthias Maier, Walter Sekundo, Dirk Sandner, Andrew Shirlaw, Lars-Olof Hattenbach
JournalOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde (Ophthalmologica) Vol. 233 Issue 1 Pg. 18-26 ( 2015) ISSN: 1423-0267 [Electronic] Switzerland
PMID25503473 (Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't)
Copyright© 2014 S. Karger AG, Basel.
Chemical References
  • Drug Implants
  • Glucocorticoids
  • Dexamethasone
  • Aged
  • Aged, 80 and over
  • Dexamethasone (administration & dosage, adverse effects)
  • Drug Implants
  • Female
  • Glucocorticoids (administration & dosage, adverse effects)
  • Humans
  • Intraocular Pressure (drug effects)
  • Intravitreal Injections
  • Macular Edema (drug therapy, etiology)
  • Male
  • Middle Aged
  • Retinal Vein Occlusion (complications)
  • Retreatment
  • Retrospective Studies
  • Visual Acuity (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: